[Latest] Global Injectable Drug Delivery Devices Market Size/Share Worth USD 40,956.3 Million by 2033 at a 10.21% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
25 nov. 2024 11h30 HE
|
Custom Market Insights
Austin, TX, USA, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Injectable Drug Delivery Devices Market Size, Trends and Insights By Device Type...
Insignis Therapeutics Receives Positive FDA Feedback on IN-001 Clinical Program for Needle-Free Anaphylaxis Treatment
05 nov. 2024 08h00 HE
|
Insignis Therapeutics, Inc.
Insignis Therapeutics advances IN-001, a needle-free anaphylaxis treatment, following FDA’s positive feedback and Fast Track designation.
Insignis Therapeutics Announces Positive Results from Phase 1 Clinical Study of IN-001 Liquid Epinephrine Sublingual Spray for Anaphylaxis
07 oct. 2024 08h00 HE
|
Insignis Therapeutics, Inc.
Insignis' Phase 1 trial shows IN-001 spray quickly reaches target epinephrine levels, sustained for 2 hours, offering a reliable needle-free alternative.
Insignis Therapeutics Receives FDA Fast Track Designation for IN-001 for Anaphylaxis Treatment
13 août 2024 07h30 HE
|
Insignis Therapeutics, Inc.
Insignis’ liquid epinephrine sublingual spray for anaphylaxis, stable and usable under both extreme heat and cold, gains FDA Fast Track designation.
Crossject franchit une nouvelle étape clé dans la fabrication de ZEPIZURE®
18 juil. 2024 01h30 HE
|
CROSSJECT
Fabrication réussie d’un autre Lot Règlementaire de ZEPIZURE® sur le nouveau site de fabricationUne étape importante qui complète les résultats satisfaisants obtenus avec les lots précédents dans le...
Crossject achieves key ZEPIZURE® manufacturing milestone
18 juil. 2024 01h30 HE
|
CROSSJECT
Successful completion of an additional Registration Batch of ZEPIZURE® at new manufacturing siteMilestone complements the satisfying results from previous batches under stability studies, and is...
Needle-free vaccine delivery platform aims to end frozen storage needs and improve access
06 juin 2023 04h00 HE
|
aVaxziPen
CEPI to initially provide up to US$1.6 million to aVaxziPen to advance development of needle-free vaccine technology aVaxziPen’s innovative vaccine delivery platform aims to improve access to...
aVaxziPen Announces Positive Data in Multiple Diseases on Novel Needle-Free Vaccine, Thermally Stable Delivery Platform at World Vaccine Congress
03 avr. 2023 03h00 HE
|
aVaxziPen
OXFORD, United Kingdom, April 03, 2023 (GLOBE NEWSWIRE) -- aVaxziPen, a biotech company developing a novel needle-free vaccine delivery platform, announces the presentation of data at the World...
University Hospitals Joins Needle-Free Blood Draw Movement, Adopts PIVO™
18 juil. 2018 08h00 HE
|
University Hospitals Cleveland Medical Center
CLEVELAND, July 18, 2018 (GLOBE NEWSWIRE) -- As part of its ongoing commitment to provide high-quality, patient-centered medical care, University Hospitals (UH) today announced that it has...
Initiation of Phase 3 Clinical Trial on the Patient-controlled Pain Management Drug "SyB P-1501"
13 juin 2016 01h18 HE
|
SymBio Pharmaceuticals Ltd
TOKYO, June 13, 2016 (GLOBE NEWSWIRE) -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, “SymBio”) announced today that the Phase 3 clinical trial on “SyB P-1501” – a drug for...